Mizuho Nagao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mizuho Nagao has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Takao Fujisawa
National Hospital Organization, Mie National Hospital, Tsu, Japan
17 shared publications - Keigo Kainuma
ENGAGE‐Task Force Tokyo Japan
5 shared publications - Amir Hamzah Abdul Latiff
Allergy & Immunology Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
4 shared publications - Iris Rengganis
Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia
4 shared publications - Jiu-Yao Wang
Research Center of Allergy, Immunology and Microbiome (A.I.M.), China Medical University Hospital, China Medical University, Taichung, Taiwan
4 shared publications - Luo Zhang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3380
Smartwatch-Derived Nocturnal Scratching Metrics Capture Disease Activity and Severity in Pediatric Atopic Dermatitis
Background/Objectives: The itch–scratch cycle is a key driver of exacerbation in atopic dermatitis (AD) and requires objective monitoring, yet patient-reported itch scores are often unreliable in children. This study aimed to evaluate smartwatch-derived nocturnal scratching metrics as digital biomarkers of disease activity and treatment response in pediatric AD. Methods: In this prospective observational study, 50 children (median age 9 years) with physician-diagnosed AD wore an Apple Watch with the Itch Tracker application for 5–14 nights during initiation of topical therapy. Three scratch metrics—scratch count rate (SCR), scratch duration ratio (SDR), and scratch burden index (SBI, duration × intensity)—were analyzed. Associations with clinical outcomes [Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM)], serum thymus and activation-regulated chemokine (TARC), and itch numerical rating scale (NRS) were examined. Logistic regression models were evaluated to examine whether these metrics could identify children who achieved clinically meaningful improvement, defined as EASI-50 plus ≥ 4-point POEM reduction. Results: All scratch metrics correlated with baseline EASI (r = 0.60–0.64, p < 0.001) and serum TARC (r = 0.58–0.60, p < 0.001). Reductions in scratching paralleled clinical improvement (r = 0.67–0.71, p < 0.0001). Among models, the SBI-based logistic regression demonstrated the best discriminative performance (AUC = 0.78, 95% CI: 0.64–0.92). Conclusions: Wearable-derived nocturnal scratching metrics showed moderate but consistent associations with disease severity and short-term improvement. Although predictive capability remains to be established, these metrics may serve as treatment-responsive digital measures. Given the cross-sectional nature of biomarker analyses and other study limitations, further prospective validation is required before clinical application in real-world pediatric AD monitoring.
- 28 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3380
Open AccessSmartwatch-Derived Nocturnal Scratching Metrics Capture Disease Activity and Severity in Pediatric Atopic Dermatitis
Background/Objectives: The itch–scratch cycle is a key driver of exacerbation in atopic dermatitis (AD) and requires objective monitoring, yet patient-reported itch scores are often unreliable in children. This study aimed to evaluate smartwatch-derived nocturnal scratching metrics as digital biomarkers of disease activity and treatment response in pediatric AD. Methods: In this prospective observational study, 50 children (median age 9 years) with physician-diagnosed AD wore an Apple Watch with the Itch Tracker application for 5–14 nights during initiation of topical therapy. Three scratch metrics—scratch count rate (SCR), scratch duration ratio (SDR), and scratch burden index (SBI, duration × intensity)—were analyzed. Associations with clinical outcomes [Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM)], serum thymus and activation-regulated chemokine (TARC), and itch numerical rating scale (NRS) were examined. Logistic regression models were evaluated to examine whether these metrics could identify children who achieved clinically meaningful improvement, defined as EASI-50 plus ≥ 4-point POEM reduction. Results: All scratch metrics correlated with baseline EASI (r = 0.60–0.64, p < 0.001) and serum TARC (r = 0.58–0.60, p < 0.001). Reductions in scratching paralleled clinical improvement (r = 0.67–0.71, p < 0.0001). Among models, the SBI-based logistic regression demonstrated the best discriminative performance (AUC = 0.78, 95% CI: 0.64–0.92). Conclusions: Wearable-derived nocturnal scratching metrics showed moderate but consistent associations with disease severity and short-term improvement. Although predictive capability remains to be established, these metrics may serve as treatment-responsive digital measures. Given the cross-sectional nature of biomarker analyses and other study limitations, further prospective validation is required before clinical application in real-world pediatric AD monitoring.
- Open Access
- 3 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4727
Predictors of Long-Term Desensitization in Children Treated with Oral Immunotherapy for Food Allergy: A Real-World Cohort Study
Background: The degree of desensitization achieved through oral immunotherapy (OIT) varies widely. This study aimed to identify factors predictive of full desensitization—defined as daily, symptom-free consumption of allergenic foods—in children with food allergies under real-world conditions. Methods: A follow-up survey was conducted for all children who received OIT at Mie National Hospital, Japan, between 2008 and 2017, to assess long-term safety. Patients treated for hen’s egg, cow’s milk, or wheat allergy with at least five years of follow-up were included in the analysis. Data were collected from surveys and medical records, including treatment-emergent adverse events (TEAEs), baseline allergen-specific IgE (sIgE), and daily intake of allergenic foods. TEAEs were evaluated using the World Allergy Organization grading system. Full desensitization was defined as the ability to consume a typical daily portion of allergenic food without symptoms. Predictive factors were identified by multivariate logistic regression. Results: A total of 111 patients (142 OIT courses: egg n = 72, milk n = 47, wheat n = 23) met inclusion criteria. The median age at OIT initiation was 6 years (IQR: 5–8). No TEAEs of grade 4 or grade 5 were reported. Overall, 30% of them achieved full desensitization: 32% in the egg group, 24% in the milk group, and 39% in the wheat group. Low baseline sIgE and absence of mild oral symptoms during build-up were identified as significant predictors. Conclusions: Mild oral symptoms may signal lower likelihood of success. Monitoring them may support individualized OIT.
- 3 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4727
Open AccessPredictors of Long-Term Desensitization in Children Treated with Oral Immunotherapy for Food Allergy: A Real-World Cohort Study
Background: The degree of desensitization achieved through oral immunotherapy (OIT) varies widely. This study aimed to identify factors predictive of full desensitization—defined as daily, symptom-free consumption of allergenic foods—in children with food allergies under real-world conditions. Methods: A follow-up survey was conducted for all children who received OIT at Mie National Hospital, Japan, between 2008 and 2017, to assess long-term safety. Patients treated for hen’s egg, cow’s milk, or wheat allergy with at least five years of follow-up were included in the analysis. Data were collected from surveys and medical records, including treatment-emergent adverse events (TEAEs), baseline allergen-specific IgE (sIgE), and daily intake of allergenic foods. TEAEs were evaluated using the World Allergy Organization grading system. Full desensitization was defined as the ability to consume a typical daily portion of allergenic food without symptoms. Predictive factors were identified by multivariate logistic regression. Results: A total of 111 patients (142 OIT courses: egg n = 72, milk n = 47, wheat n = 23) met inclusion criteria. The median age at OIT initiation was 6 years (IQR: 5–8). No TEAEs of grade 4 or grade 5 were reported. Overall, 30% of them achieved full desensitization: 32% in the egg group, 24% in the milk group, and 39% in the wheat group. Low baseline sIgE and absence of mild oral symptoms during build-up were identified as significant predictors. Conclusions: Mild oral symptoms may signal lower likelihood of success. Monitoring them may support individualized OIT.
- 19 May 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (5) , e70105
Low‐dose oral cow's milk challenge outcome for patients on complete avoidance: A multicenter study in Japan
Background: Few studies have reported significant risk factors for allergic symptoms during low‐dose (1–3 mL) cow's milk (CM) oral food challenges (OFCs). We investigated patients from multiple centers in Japan to identify high‐risk, low‐dose CM OFCs and conducted these tests at allergy‐specialized facilities. Methods: We retrospectively collected the results of the first low‐dose CM OFCs performed at 10 hospitals in Japan between January and December 2019. All patients completely eliminated CM and underwent low‐dose CM OFCs. The risk factors for positive OFC and anaphylaxis were analyzed using logistic regression analyses. Results: We included 244 patients (median age: 2.5 years). The median level of CM‐specific immunoglobulin E (sIgE) was 13.1 (interquartile range: 3.7–45.6) kU A /L. The rates of positive and anaphylaxis among positive for CM OFCs were 44% and 19%, respectively. Multivariate analyses that separately analyzed each sIgE identified high CM sIgE and casein sIgE levels as significant risk factors for OFC positivity (both p < .001). The optimal cut‐off values for CM and casein sIgE levels to predict positive CM OFCs from receiver operating characteristic curves were 5.4 and 7.3 kU A /L, respectively. When CM sIgE or casein sIgE levels were ≥10.9 kU A /L or ≥ 11.5 kU A /L, they corresponded to 5% predicted probabilities of anaphylaxis. Furthermore, when their levels are ≥100 kU A /L, the predicted probabilities increase to 20%. Conclusion: CM and casein sIgE levels should be considered when predicting low‐dose CM OFC outcomes.
- 19 May 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (5) , e70105
Low‐dose oral cow's milk challenge outcome for patients on complete avoidance: A multicenter study in Japan
Background: Few studies have reported significant risk factors for allergic symptoms during low‐dose (1–3 mL) cow's milk (CM) oral food challenges (OFCs). We investigated patients from multiple centers in Japan to identify high‐risk, low‐dose CM OFCs and conducted these tests at allergy‐specialized facilities. Methods: We retrospectively collected the results of the first low‐dose CM OFCs performed at 10 hospitals in Japan between January and December 2019. All patients completely eliminated CM and underwent low‐dose CM OFCs. The risk factors for positive OFC and anaphylaxis were analyzed using logistic regression analyses. Results: We included 244 patients (median age: 2.5 years). The median level of CM‐specific immunoglobulin E (sIgE) was 13.1 (interquartile range: 3.7–45.6) kU A /L. The rates of positive and anaphylaxis among positive for CM OFCs were 44% and 19%, respectively. Multivariate analyses that separately analyzed each sIgE identified high CM sIgE and casein sIgE levels as significant risk factors for OFC positivity (both p < .001). The optimal cut‐off values for CM and casein sIgE levels to predict positive CM OFCs from receiver operating characteristic curves were 5.4 and 7.3 kU A /L, respectively. When CM sIgE or casein sIgE levels were ≥10.9 kU A /L or ≥ 11.5 kU A /L, they corresponded to 5% predicted probabilities of anaphylaxis. Furthermore, when their levels are ≥100 kU A /L, the predicted probabilities increase to 20%. Conclusion: CM and casein sIgE levels should be considered when predicting low‐dose CM OFC outcomes.
- Open Access
- 16 May 2025
- Published by MDPI AG in Preprints.org
Predictors of Long-Term Desensitization in Children Treated with Oral Immunotherapy for Food Allergy: A Real-World Cohort Study
Background: The degree of desensitization achieved through oral immunotherapy (OIT) varies widely. This study aimed to identify factors predictive of full desensitization—defined as daily, symptom-free consumption of allergenic foods—in children with food allergies under real-world conditions. Methods: A follow-up survey was conducted for all children who received OIT at Mie National Hospital, Japan, between 2008 and 2017, to assess long-term safety. Patients treated for hen’s egg, cow’s milk, or wheat allergy with at least five years of follow-up were included in the analysis. Data were collected from surveys and medical records, including treatment-emergent adverse events (TEAEs), baseline allergen-specific IgE (sIgE), and daily intake of allergenic foods. TEAEs were evaluated using the World Allergy Organization grading system. Full desensitization was defined as the ability to consume a typical daily portion of the allergenic food without symptoms. Predictive factors were identified by multivariate logistic regression. Results: A total of 111 patients (142 OIT courses: egg n = 72, milk n = 47, wheat n = 23) met inclusion criteria. The median age at OIT initiation was 6 years (IQR: 5–8). No TEAEs of grade 4 or 5 were reported. Overall, 30% of them achieved full desensitization: 32% in the egg group, 24% in the milk group, and 39% in the wheat group. Low baseline sIgE and absence of mild oral symptoms during build-up were identified as significant predictors. Conclusions: Mild oral symptoms may signal lower likelihood of success. Monitoring them may support individualized OIT.
- 16 May 2025
- Published by MDPI AG in Preprints.org
Open AccessPredictors of Long-Term Desensitization in Children Treated with Oral Immunotherapy for Food Allergy: A Real-World Cohort Study
Background: The degree of desensitization achieved through oral immunotherapy (OIT) varies widely. This study aimed to identify factors predictive of full desensitization—defined as daily, symptom-free consumption of allergenic foods—in children with food allergies under real-world conditions. Methods: A follow-up survey was conducted for all children who received OIT at Mie National Hospital, Japan, between 2008 and 2017, to assess long-term safety. Patients treated for hen’s egg, cow’s milk, or wheat allergy with at least five years of follow-up were included in the analysis. Data were collected from surveys and medical records, including treatment-emergent adverse events (TEAEs), baseline allergen-specific IgE (sIgE), and daily intake of allergenic foods. TEAEs were evaluated using the World Allergy Organization grading system. Full desensitization was defined as the ability to consume a typical daily portion of the allergenic food without symptoms. Predictive factors were identified by multivariate logistic regression. Results: A total of 111 patients (142 OIT courses: egg n = 72, milk n = 47, wheat n = 23) met inclusion criteria. The median age at OIT initiation was 6 years (IQR: 5–8). No TEAEs of grade 4 or 5 were reported. Overall, 30% of them achieved full desensitization: 32% in the egg group, 24% in the milk group, and 39% in the wheat group. Low baseline sIgE and absence of mild oral symptoms during build-up were identified as significant predictors. Conclusions: Mild oral symptoms may signal lower likelihood of success. Monitoring them may support individualized OIT.
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (1) , 44-49
COVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work–life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- 1 March 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (1) , 44-49
Open AccessCOVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work–life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health
- Vol. 13 (1) , 44-49
COVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work-life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- 1 March 2023
- Published by Wolters Kluwer Health
- Vol. 13 (1) , 44-49
Open AccessCOVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work-life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- Open Access
A Murine Model of Food Allergy by Epicutaneous Adjuvant-Free Allergen Sensitization Followed by Oral Allergen Challenge Combined with Aspirin for Enhanced Detection of Hypersensitivity Manifestations and Immunotherapy Monitoring
Food allergy is one of the major existing health problems, but no effective treatment is available. In the current work, a murine model that closely mimics pathogenesis of human food allergy and its quantifiable diagnostic parameter design, even for mild hypersensitivity reactions, were established. BALB/c mice were epicutaneously sensitized with 1 mg chicken egg ovomucoid (OVM) or cow’s milk casein, free of adjuvants, five times a week for two consecutive weeks. Eleven days later, allergen-specific IgG1 and IgE in serum were measured by ELISA. On day 25, 20 mg OVM or 12 mg α-casein was administered orally, and allergic reactions such as the fall in rectal temperature, symptom scores during 90–120 min, serum mast cell protease-1 and cytokine levels were monitored. The detection of mild allergic reactions due to adjuvant-free allergen sensitization and oral allergen challenge routes was amplified by the combination of oral allergen and aspirin administration simultaneously or aspirin administration within 15–30 min before an allergen challenge. Quantification of the maximum symptom score and the frequency of symptoms during the monitoring period improved evaluation accuracy of food allergy signals. Based on these results, efficacy of casein oral immunotherapy for cow’s milk allergies, which are generally difficult to detect, was monitored adequately.
Open AccessA Murine Model of Food Allergy by Epicutaneous Adjuvant-Free Allergen Sensitization Followed by Oral Allergen Challenge Combined with Aspirin for Enhanced Detection of Hypersensitivity Manifestations and Immunotherapy Monitoring
Food allergy is one of the major existing health problems, but no effective treatment is available. In the current work, a murine model that closely mimics pathogenesis of human food allergy and its quantifiable diagnostic parameter design, even for mild hypersensitivity reactions, were established. BALB/c mice were epicutaneously sensitized with 1 mg chicken egg ovomucoid (OVM) or cow’s milk casein, free of adjuvants, five times a week for two consecutive weeks. Eleven days later, allergen-specific IgG1 and IgE in serum were measured by ELISA. On day 25, 20 mg OVM or 12 mg α-casein was administered orally, and allergic reactions such as the fall in rectal temperature, symptom scores during 90–120 min, serum mast cell protease-1 and cytokine levels were monitored. The detection of mild allergic reactions due to adjuvant-free allergen sensitization and oral allergen challenge routes was amplified by the combination of oral allergen and aspirin administration simultaneously or aspirin administration within 15–30 min before an allergen challenge. Quantification of the maximum symptom score and the frequency of symptoms during the monitoring period improved evaluation accuracy of food allergy signals. Based on these results, efficacy of casein oral immunotherapy for cow’s milk allergies, which are generally difficult to detect, was monitored adequately.
- Open Access
- 1 January 2023
- Published by Japan Medical Association in JMA Journal
- Vol. 6 (2) , 165-174
Prevalence of Allergic Diseases across All Ages in Japan: A Nationwide Cross-Sectional Study Employing Designated Allergic Disease Medical Hospital Network
Allergic diseases affect both children and adults, but generation-specific prevalence rates are unclear. An online questionnaire was used from December 2021 to January 2022 to survey the prevalence of allergic diseases among staff and their families of designated allergic disease medical hospitals in Japan. In this study, bronchial asthma (BA), atopic dermatitis (AD), food allergies (FAs), allergic rhinitis (AR), allergic conjunctivitis (AC), metal allergies (MAs), and drug allergies (DAs) were the allergic diseases surveyed. In total, 18,706 individuals were surveyed (median age, 36 years; quartile range, 18-50). Allergic disease was reported in 62.2% of respondents. Across all ages, prevalence rates were as follows: BA (14.7%), AD (15.6%), FAs (15.2%), AR (47.4%), AC (19.5%), MAs (1.9%), and DAs (4.6%). The prevalence of BA and AR was higher in male children, whereas that of FAs and AC was higher in adult females. The prevalence of MAs and DAs peaked during adulthood and predominated among females. Our results suggest that approximately two-thirds of the Japanese population may have an allergic disease, with AR being the most prevalent.
- 1 January 2023
- Published by Japan Medical Association in JMA Journal
- Vol. 6 (2) , 165-174
Open AccessPrevalence of Allergic Diseases across All Ages in Japan: A Nationwide Cross-Sectional Study Employing Designated Allergic Disease Medical Hospital Network
Allergic diseases affect both children and adults, but generation-specific prevalence rates are unclear. An online questionnaire was used from December 2021 to January 2022 to survey the prevalence of allergic diseases among staff and their families of designated allergic disease medical hospitals in Japan. In this study, bronchial asthma (BA), atopic dermatitis (AD), food allergies (FAs), allergic rhinitis (AR), allergic conjunctivitis (AC), metal allergies (MAs), and drug allergies (DAs) were the allergic diseases surveyed. In total, 18,706 individuals were surveyed (median age, 36 years; quartile range, 18-50). Allergic disease was reported in 62.2% of respondents. Across all ages, prevalence rates were as follows: BA (14.7%), AD (15.6%), FAs (15.2%), AR (47.4%), AC (19.5%), MAs (1.9%), and DAs (4.6%). The prevalence of BA and AR was higher in male children, whereas that of FAs and AC was higher in adult females. The prevalence of MAs and DAs peaked during adulthood and predominated among females. Our results suggest that approximately two-thirds of the Japanese population may have an allergic disease, with AR being the most prevalent.
- Open Access
Risk Factors for Lung Function Decline in Pediatric Asthma under Treatment: A Retrospective, Multicenter, Observational Study
Background: Childhood asthma is a major risk for low lung function in later adulthood, but what factors in asthma are associated with the poor lung function during childhood is not known. Objective: To identify clinical factors in children with asthma associated with low or declining lung function during the treatment. Methods: We enrolled children with asthma who had been treated throughout three age periods, i.e., 6–9, 10–12, and 13–15 years old, at seven specialized hospitals in Japan. Clinical information and lung function measurements were retrieved from the electronic chart systems. To characterize the lung function trajectories during each age period, we evaluated the forced expiratory volume 1 (FEV1) with % predicted values and individual changes by the slope (S) from linear regression. We defined four trajectory patterns: normal (Group N) and low (Group L), showing %FEV1 ≥80% or n = 150)/U (n = 47), while 76 (28%) were in Group D (n = 66)/L (n = 10). A history of poor asthma control, long-acting beta2 agonist use, and a lower height Z-score during 13–15 years were associated with an unfavorable outcome (Group D/L). Conversely, inhaled corticosteroid (ICS) use during 10–12 years and high-dose ICS use during 13–15 years were associated with a favorable outcome (Group N/U). Conclusion: We identified several factors that are associated with unfavorable lung function changes in pediatric asthma. Attention should be paid to the possible relationship between yearly changes in lung function and poor asthma control, use of ICS (and its dose) and use of LABA.
Open AccessRisk Factors for Lung Function Decline in Pediatric Asthma under Treatment: A Retrospective, Multicenter, Observational Study
Background: Childhood asthma is a major risk for low lung function in later adulthood, but what factors in asthma are associated with the poor lung function during childhood is not known. Objective: To identify clinical factors in children with asthma associated with low or declining lung function during the treatment. Methods: We enrolled children with asthma who had been treated throughout three age periods, i.e., 6–9, 10–12, and 13–15 years old, at seven specialized hospitals in Japan. Clinical information and lung function measurements were retrieved from the electronic chart systems. To characterize the lung function trajectories during each age period, we evaluated the forced expiratory volume 1 (FEV1) with % predicted values and individual changes by the slope (S) from linear regression. We defined four trajectory patterns: normal (Group N) and low (Group L), showing %FEV1 ≥80% or n = 150)/U (n = 47), while 76 (28%) were in Group D (n = 66)/L (n = 10). A history of poor asthma control, long-acting beta2 agonist use, and a lower height Z-score during 13–15 years were associated with an unfavorable outcome (Group D/L). Conversely, inhaled corticosteroid (ICS) use during 10–12 years and high-dose ICS use during 13–15 years were associated with a favorable outcome (Group N/U). Conclusion: We identified several factors that are associated with unfavorable lung function changes in pediatric asthma. Attention should be paid to the possible relationship between yearly changes in lung function and poor asthma control, use of ICS (and its dose) and use of LABA.
- Open Access
- 1 October 2021
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 11 (4)
Squamous cell carcinoma antigens are sensitive biomarkers for atopic dermatitis in children and adolescents: a cross-sectional study
Background: We recently reported that squamous cell carcinoma antigen 2 (SCCA2) is a reliable biomarker for atopic dermatitis (AD). Objective: To further clarify its utility, we investigated for effects of comorbid allergies and AD treatment on serum SCCA levels. Methods: Volunteers R2 values of 0.16, 0.38, and 0.48 for TARC, SCCA1, and SCCA2, respectively. Conclusion: SCCAs, especially SCCA2, are sensitive biomarkers for detecting AD in children and adolescents and for assessing the severity and response to treatment of severe AD.
- 1 October 2021
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 11 (4)
Open AccessSquamous cell carcinoma antigens are sensitive biomarkers for atopic dermatitis in children and adolescents: a cross-sectional study
Background: We recently reported that squamous cell carcinoma antigen 2 (SCCA2) is a reliable biomarker for atopic dermatitis (AD). Objective: To further clarify its utility, we investigated for effects of comorbid allergies and AD treatment on serum SCCA levels. Methods: Volunteers R2 values of 0.16, 0.38, and 0.48 for TARC, SCCA1, and SCCA2, respectively. Conclusion: SCCAs, especially SCCA2, are sensitive biomarkers for detecting AD in children and adolescents and for assessing the severity and response to treatment of severe AD.